On June 19, 2014, Cara Therapeutics Inc (NASDAQ:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, announced that Eric J. Vandal has been named Vice President, Commercial Operations. Mr. Vandal will assume responsibility for developing and implementing commercialization and marketing strategies in support of Cara’s clinical development programs. Cara Therapeutics Inc (NASDAQ:CARA), net profit margin is -25.20% and weekly performance is 22.79%. On last trading day company shares ended up $17.51. Analysts mean target price for the company is $22.75. Cara Therapeutics Inc (NASDAQ:CARA), distance from 50-day simple moving average (SMA50) is 22.69%.
TG Therapeutics, Inc. (NASDAQ:TGTX), advanced 6.98% in last trading session and ended the day on $8.58. TGTX, return on assets is -54.70%. TG Therapeutics, Inc. (NASDAQ:TGTX), quarterly performance is 23.10%.
On June 17, 2014, Cempra Inc (NASDAQ:CEMP), announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at the JMP Securities Healthcare Conference at 10:30 a.m. EDT, Tuesday, June 24, at The Westin New York Grand Central in New York City. Cempra Inc (NASDAQ:CEMP), shares moved up 5.27% in last trading session and was closed at $10.98, while trading in range of $ 10.32 – 11.14. Cempra Inc (NASDAQ:CEMP), year to date (YTD) performance is -11.38%.
Cubist Pharmaceuticals Inc (NASDAQ:CBST)’s shares climbed 4.30% to $71.50. The company on June 19 announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for its investigational antibiotic ceftolozane/tazobactam with Priority Review. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of December 21, 2014. Cubist Pharmaceuticals Inc (NASDAQ:CBST), ended the last trading day at $72.24. Company weekly volatility is calculated as 2.33% and price to cash ratio as 9.61. Cubist Pharmaceuticals Inc (NASDAQ:CBST), showed a positive weekly performance of 5.14%.
Repligen Corporation (NASDAQ:RGEN), SVP Daniel P. Witt sold 47,709 shares of the stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $20.56, for a total transaction of $980,897.04. Following the completion of the sale, the senior vice president now directly owns 10,000 shares in the company, valued at approximately $205,600. Repligen Corporation (NASDAQ:RGEN), net profit margin is 26.50% and weekly performance is 11.23%. On last trading day company shares ended up $21.98. Analysts mean target price for the company is $22.50. Repligen Corporation (NASDAQ:RGEN), distance from 50-day simple moving average (SMA50) is 24.22%.